NASDAQ:APGE Apogee Therapeutics (APGE) Stock Price, News & Analysis $27.94 -2.08 (-6.93%) (As of 12/29/2023 ET) Add Compare Share Share Today's Range$27.93▼$31.6250-Day Range$15.00▼$31.0752-Week Range$14.19▼$33.08Volume266,106 shsAverage Volume312,534 shsMarket Capitalization$1.42 billionP/E RatioN/ADividend YieldN/APrice Target$35.83 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial Media Apogee Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside28.3% Upside$35.83 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews Sentiment0.65Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.70) to ($2.09) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.79 out of 5 starsMedical Sector764th out of 950 stocksBiological Products, Except Diagnostic Industry136th out of 158 stocks 3.5 Analyst's Opinion Consensus RatingApogee Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $35.83, Apogee Therapeutics has a forecasted upside of 28.3% from its current price of $27.94.Amount of Analyst CoverageApogee Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for APGE. Previous Next 0.0 Dividend Strength Dividend YieldApogee Therapeutics does not currently pay a dividend.Dividend GrowthApogee Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for APGE. Previous Next 2.6 News and Social Media Coverage News SentimentApogee Therapeutics has a news sentiment score of 0.65. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.84 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Apogee Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 3 people have searched for APGE on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows4 people have added Apogee Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Apogee Therapeutics insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 32.06% of the stock of Apogee Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Apogee Therapeutics are expected to grow in the coming year, from ($2.70) to ($2.09) per share. Previous Next See Top Rated MarketRank™ Stocks Here About Apogee Therapeutics Stock (NASDAQ:APGE)Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.Read More APGE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart APGE Stock News HeadlinesDecember 31, 2023 | americanbankingnews.comApogee Therapeutics (NASDAQ:APGE) Stock Price Up 2.5%December 26, 2023 | americanbankingnews.comCritical Survey: Apogee Therapeutics (NASDAQ:APGE) and Sutro Biopharma (NASDAQ:STRO)December 31, 2023 | MarketBeat Internal (Ad)MarketBeat All Access New Year's Sale - Just $1.00Access our premier research platform that includes MarketBeat Daily Premium, portfolio monitoring tools, stock screeners, research tools, a real-time news feed, email and SMS alerts, the MarketBeat Idea Engine, proprietary brokerage rankings, extended data export tools and much more. Save 75% Your 2024 Subscription. Just $1.00 for the first 30 days.December 24, 2023 | americanbankingnews.comApogee Therapeutics (NASDAQ:APGE) Stock Price Up 6.6%December 23, 2023 | americanbankingnews.comApogee Therapeutics (NASDAQ:APGE) Hits New 12-Month High at $25.85December 22, 2023 | benzinga.comApogee Therapeutics Stock (NASDAQ:APGE), Analyst Ratings, Price Targets, PredictionsDecember 21, 2023 | benzinga.comApogee Therapeutics Stock (NASDAQ:APGE) Dividends: History, Yield and DatesDecember 21, 2023 | americanbankingnews.comApogee Therapeutics (NASDAQ:APGE) Receives New Coverage from Analysts at BTIG ResearchDecember 31, 2023 | MarketBeat Internal (Ad)MarketBeat All Access New Year's Sale - Just $1.00Access our premier research platform that includes MarketBeat Daily Premium, portfolio monitoring tools, stock screeners, research tools, a real-time news feed, email and SMS alerts, the MarketBeat Idea Engine, proprietary brokerage rankings, extended data export tools and much more. Save 75% Your 2024 Subscription. Just $1.00 for the first 30 days.December 15, 2023 | bizjournals.comLexington diabetes drug, device maker files for IPO — a rarity in 2023November 28, 2023 | markets.businessinsider.comApogee Therapeutics, Inc.: Outshining Lebrikizumab with APG777’s Enhanced Efficacy and Quarterly Dosing AdvantageNovember 21, 2023 | finance.yahoo.comWe Think Apogee Therapeutics (NASDAQ:APGE) Can Easily Afford To Drive Business GrowthNovember 15, 2023 | finance.yahoo.comApogee Therapeutics Inc Reports Q3 2023 Financial Results and Corporate ProgressNovember 13, 2023 | finance.yahoo.comApogee Highlights Corporate Progress and Reports Third Quarter 2023 Financial ResultsNovember 8, 2023 | morningstar.comApogee Therapeutics Inc APGENovember 2, 2023 | bizjournals.comA handful of biotechs have finally held IPOs. Will more follow?October 30, 2023 | finance.yahoo.comApogee Therapeutics to Participate in Upcoming November Investor ConferencesOctober 24, 2023 | finanznachrichten.deApogee Therapeutics Announces IPO Of 15.625 Mln Shares To Be Priced Between $15.00 And $17.00/ShareSeptember 27, 2023 | finance.yahoo.comApogee Announces Two Abstracts Accepted for Presentation at the 2023 European Academy of Dermatology and Venereology (EADV) CongressSeptember 15, 2023 | bizjournals.comA biotech holds a $250M IPO, stoking flames of hope for industry watchersSeptember 14, 2023 | finance.yahoo.comApogee Therapeutics to Participate at the 2023 Stifel Virtual I&I DayAugust 29, 2023 | finance.yahoo.comParagon Therapeutics Recognizes Key Milestones and Leadership Appointment for First Spinout, Apogee TherapeuticsAugust 28, 2023 | finance.yahoo.comApogee Highlights Corporate Progress and Reports Second Quarter 2023 Financial ResultsAugust 22, 2023 | seekingalpha.comApogee Therapeutics: Potential To Target Autoimmune Disorders With Less Frequent DosingAugust 21, 2023 | seekingalpha.comApogee Therapeutics appoints Mark C. Mckenna as Chairman of its boardAugust 21, 2023 | finance.yahoo.comApogee Therapeutics Appoints Mark C. McKenna, Healthcare Veteran and Former Chairman, President and CEO of Prometheus Biosciences, as Chairman of its BoardAugust 7, 2023 | finance.yahoo.comApogee Announces First Participants Dosed Ahead of Schedule in Phase 1 Trial of APG777, its Novel Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory DiseasesSee More Headlines Receive APGE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Apogee Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/13/2023Today12/31/2023Fiscal Year End12/31/2023Next Earnings (Estimated)2/12/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:APGE CUSIPN/A CIK1974640 Webwww.apogeetherapeutics.com Phone650-394-5230FaxN/AEmployees25Year FoundedN/APrice Target and Rating Average Stock Price Target$35.83 High Stock Price Target$43.00 Low Stock Price Target$29.00 Potential Upside/Downside+28.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio24.82 Quick Ratio24.82 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares50,670,000Free FloatN/AMarket Cap$1.42 billion OptionableNot Optionable BetaN/A Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesDr. Michael Thomas Henderson M.D. (Age 34)CEO & Director Comp: $369.71kDr. Carl Linden Dambkowski M.D. (Age 38)Chief Medical Officer Comp: $389.18kMs. Jane Pritchett V. Henderson (Age 57)Chief Financial Officer Dr. Rebecca Dabora Ph.D. (Age 64)Chief Technical Officer Ms. Noel KurdiVice President of Investor RelationsMr. Matthew Batters J.D. (Age 47)General Counsel Ms. Emily CoxVP & Head of PeopleMs. Wendy Aspden-CurranSenior Vice President of Clinical OperationsDr. Drew Badger Ph.D.Senior VP and Head of Regulatory Affairs & ToxicologyMs. Monica Forbes (Age 47)Senior Vice President of Finance More ExecutivesKey CompetitorsKymera TherapeuticsNASDAQ:KYMRScholar RockNASDAQ:SRRKRelay TherapeuticsNASDAQ:RLAYInhibrxNASDAQ:INBXVir BiotechnologyNASDAQ:VIRView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 1,121,764 shares on 12/18/2023Ownership: 2.214%Teachers Retirement System of The State of KentuckyBought 22,248 shares on 12/13/2023Ownership: 0.044%Wellington Management Group LLPBought 1,586,729 shares on 12/1/2023Ownership: 3.131%Deutsche Bank AGBought 4,607 shares on 11/24/2023Ownership: 0.009%Tudor Investment Corp Et AlBought 12,515 shares on 11/16/2023Ownership: 0.025%View All Insider TransactionsView All Institutional Transactions APGE Stock Analysis - Frequently Asked Questions Should I buy or sell Apogee Therapeutics stock right now? 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Apogee Therapeutics in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" APGE shares. View APGE analyst ratings or view top-rated stocks. What is Apogee Therapeutics' stock price target for 2024? 7 Wall Street research analysts have issued 12 month price targets for Apogee Therapeutics' shares. Their APGE share price targets range from $29.00 to $43.00. On average, they expect the company's stock price to reach $35.83 in the next twelve months. This suggests a possible upside of 28.3% from the stock's current price. View analysts price targets for APGE or view top-rated stocks among Wall Street analysts. How have APGE shares performed in 2023? Apogee Therapeutics' stock was trading at $21.23 at the start of the year. Since then, APGE stock has increased by 31.6% and is now trading at $27.94. View the best growth stocks for 2023 here. When is Apogee Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, February 12th 2024. View our APGE earnings forecast. How were Apogee Therapeutics' earnings last quarter? Apogee Therapeutics, Inc. (NASDAQ:APGE) released its earnings results on Monday, November, 13th. The company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.43) by $0.08. When did Apogee Therapeutics IPO? (APGE) raised $282 million in an IPO on Friday, July 14th 2023. The company issued 17,650,000 shares at a price of $15.00-$17.00 per share. When does Apogee Therapeutics' lock-up period expire? Apogee Therapeutics' lock-up period expires on Wednesday, January 10th. Apogee Therapeutics had issued 17,650,000 shares in its initial public offering on July 14th. The total size of the offering was $300,050,000 based on an initial share price of $17.00. After the end of Apogee Therapeutics' lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company will be lifted. How do I buy shares of Apogee Therapeutics? Shares of APGE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:APGE) was last updated on 12/31/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apogee Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.